GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Common Stock

Outlook Therapeutics (FRA:41O) Common Stock : €0.22 Mil (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Common Stock?

Outlook Therapeutics's quarterly common stock declined from Dec. 2023 (€2.39 Mil) to Mar. 2024 (€0.20 Mil) but then increased from Mar. 2024 (€0.20 Mil) to Jun. 2024 (€0.22 Mil).

Outlook Therapeutics's annual common stock increased from Sep. 2021 (€1.50 Mil) to Sep. 2022 (€2.30 Mil) and increased from Sep. 2022 (€2.30 Mil) to Sep. 2023 (€2.44 Mil).


Outlook Therapeutics Common Stock Historical Data

The historical data trend for Outlook Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Common Stock Chart

Outlook Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 1.08 1.50 2.30 2.44

Outlook Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.39 2.44 2.39 0.20 0.22

Outlook Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Outlook Therapeutics Business Description

Traded in Other Exchanges
Address
485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Outlook Therapeutics Headlines

No Headlines